Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis A feasibility and health economic study in an outpatient setting

Abstract

Dalteparin, administered subcutaneously, once daily, for the initial treatment of DVT yields large cost reductions and is well tolerated and effective in an outpatient setting.